Back

Effect of dapagliflozin on ventilatory control during low-intensity exercise in heart failure with preserved ejection fraction

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Exploring physiological and regional variations in HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Shunichi Doi

St. Marianna University School of Medicine, Kawasaki (Japan)

5 More presentations in this session

Presentation thumbnail
Superiority of the HFA-PEFF score over the H2FPEF score in detecting pulmonary hypertension related to left heart disease with and without elevated pulmonary artery wedge pressure
Doctor F. Bauer (Le Kremlin-Bicetre, FR)
Abstract Slides Video
Presentation thumbnail
Renal denervation for resistant hypertension in aortic coarctation: long-term impact on HFpEF risk and diastolic function
Doctor P. Sagmeister (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
The reversal of the beneficial effects of the sauna intervention on exercise capacity in patients with HFpEF within a 3-month period. Real-time data collected using wearable technology
Associate Professor T. Bekfani (Magdeburg, DE)
Abstract Slides Video
Presentation thumbnail
Sex-specific performance of HFpEF diagnostic algorithms across two independent cohorts
Doctor A. Achten (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Geographic variation in heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial
Doctor M. Vaduganathan (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Exploring physiological and regional variations in HFpEF

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources